【Industry Insights】
Lab-quality molecular diagnostic results in 30 minutes — no centralized lab, no specialized technicians, no complex sample preparation. This is no longer a distant industry vision: it is the new standard reshaping the global point-of-care testing (POCT) landscape.
1. Market Overview: The Fastest-Growing Segment in IVD
The global in vitro diagnostics (IVD) industry is undergoing a structural upgrade. While traditional rapid testing has long relied on lateral flow antigen methods, molecular POCT built on microfluidic PCR chip technology has emerged as the highest-growth track.
Driven by rising demand for lab-grade, actionable results at the patient's side, the global molecular POCT market is projected to expand at a robust 10–13% compound annual growth rate (CAGR) over the next 5–7 years, on track to reach a multi-billion-dollar market size.
2. Three Core Drivers Fueling Industry Growth
(1) Clinical Upgrade: From Empirical Treatment to Precision Therapy
Empirical treatment without clear etiological diagnosis leads to delayed patient care and accelerates antimicrobial resistance (AMR), a growing global public health crisis. Clinicians worldwide are shifting toward high-multiplex syndromic testing — single-run panels that detect dozens of pathogens and resistance markers at once, turning reactive guesswork into targeted, timely treatment decisions.
(2) Care Decentralization: Extending Diagnostics to Frontline Settings
Healthcare systems globally are moving care out of centralized hospitals and into community clinics, emergency departments, and outpatient settings. This shift demands molecular diagnostic solutions that eliminate the barriers of traditional central labs: negative-pressure facilities, high-cost equipment, and dedicated lab personnel.
(3) Public Health Resilience: Rapid Response for Epidemic & Endemic Threats
Emerging infectious diseases and widespread vector-borne endemics (including dengue, chikungunya and malaria) require diagnostic tools that can be deployed seamlessly across settings — from dense urban hospital networks to remote rural and field sites.
3. Future Trends & Chenghui Medical's Full-Care-Continuum Solutions
Next-generation molecular POCT platforms must deliver on three non-negotiable priorities: high-multiplex syndromic capability, modular portable design, and coverage across the full care continuum.
Powered by our proprietary fluorescent PCR-chip technology, Chenghui Medical's portfolio delivers a true sample-to-result workflow — no complex lab infrastructure required, with uncompromised speed and multiplex precision.
Trend 1: High-Multiplex Precision for Critical & Inpatient Care
Market Need: ICUs, emergency departments and inpatient wards require comprehensive syndromic testing to rapidly diagnose complex, life-threatening infections and reduce time to targeted therapy.
Our Solution: Multi-Disc (Model: CQ-0404)
Throughput & Speed: Processes 4 samples simultaneously with a 1.0–1.5 hours turnaround time
Multiplex Capability: Detects up to 28 pathogen targets per sample in a single cartridge
Core Syndromic Panels:
26-Plex Upper Respiratory Tract Pathogen Panel
23-Plex Lower Respiratory Tract Pathogen & AMR Gene Panel
18-Plex Meningitis Pathogen Panel
26-Plex Gastrointestinal Tract Pathogen Panel
25-Plex Blood Culture Pathogen & AMR Panel (Gram-Positive, Fungi & Resistance Markers)
26-Plex Blood Culture Pathogen & AMR Panel (Gram-Negative & Resistance Markers)
10-Plex Reproductive Tract Pathogen Panel
15-Plex Human Papillomavirus (HPV) Genotyping Panel
Trend 2: Modular Portable Design for Frontline Primary Care
Market Need: Outpatient clinics, community health centers and small practices need compact, scalable, ultra-fast testing that fits into existing patient workflows without bottlenecks.
Our Solution: Flex-Disc (Model: CH-0104)
Flexibility & Speed: Compact, portable single-sample modules deliver results in 30–45 minutes
Scalable Throughput: One wireless control unit connects to up to 8 independent test modules, allowing facilities to scale capacity on demand
Multiplex Capability: Detects up to 16 pathogen targets per sample
Core Panels:
9-Plex Respiratory Tract Pathogen Panel
10-Plex Reproductive Tract Pathogen Panel
15-Plex Human Papillomavirus (HPV) Genotyping Panel
Trend 3: Cross-Setting Compatibility for Global Public Health
Both the Multi-Disc (CQ-0404) and Flex-Disc (CH-0104) platforms support dedicated public health panels, enabling flexible deployment for epidemic preparedness and endemic disease management:
8-Plex Arboviral Pathogen Nucleic Acid Detection Panel
4-Plex Malaria Pathogen Nucleic Acid Detection Panel
Shaping the Future of Precision Diagnostics
The evolution of molecular POCT is defined by three pillars: accessibility, speed, and comprehensive panel coverage. By bridging the gap between high-throughput critical care and decentralized frontline care, Chenghui Medical equips healthcare providers and partners worldwide with accurate, accessible, timely molecular diagnostic insights.
Partner With Us
For hospital networks, diagnostic distributors, and public health agencies looking to expand their molecular testing capacity across care settings, our end-to-end POCT portfolio delivers tailored solutions for every use case.
#MolecularPOCT #MolecularDiagnostics #InVitroDiagnostics #IVD #SyndromicTesting #PointOfCare #InfectiousDisease #AntimicrobialResistance #PublicHealth #GlobalHealth #MedTech #ChenghuiMedical #PCR